The leading Severe Asthma Companies such as Kinaset Therapeutics, Bio-Thera Solutions, CSPC ZhongQi Pharmaceutical Technology ...

To read more about the latest highlights related to the PDC market, get a snapshot of the key highlights entailed in the ...

Xencor Inc . (NASDAQ:XNCR), a biopharmaceutical company specializing in innovative therapies for immunology and oncology, ...

Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced ...

Recombinant antibodies are invented antibodies formed by using recombinant DNA technology. While traditional monoclonal ...

Uniform protein labeling in intact tissues is a challenge. An approach that allows antibodies to seep within organs could ...

IRVINE, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, and Steve Perrin, Ph.D., Chief Scientific ...

Eledon Pharmaceuticals has a promising anti-CD40L antibody for organ rejection prevention in transplantation. Learn more ...

In a study published in Cell, a research team led by Zhu Shujia from the Center for Excellence in Brain Science and ...

Induces potent and long-lasting immune responses to defined antigens or whole pathogens (particles), mainly through the ...

Where can researchers look for a beacon of hope amid trying times in the pharmaceutical industry? Read on for answers.

Phase III Vivacity-MG3 trial shows that nipocalimab, an investigational FcRn blocker, significantly the improves symptoms of generalized myasthenia gravis with a manageable safety profile.